Compare AbbVie Inc (ABBV) vs D R Horton Inc (DHI) Price & Performance

ABBV trades at $247.91, up 0.76% today, with a bullish technical signal supported by moving averages and oversold RSI levels. The company reported Q2 2026 EPS of $3.65, beating expectations, and maintains strong profitability with a 71.48% gross margin. Recent news highlights positive Phase 2 data for ELAHERE in ovarian cancer, reinforcing growth prospects beyond Humira's patent expiry.

Outlook is positive with analyst consensus target of $278.69, though high P/E of 70.05 and debt levels pose valuation and financial risks. Revenue growth driven by Skyrizi and Rinvoq offsets competitive pressures, but patent cliffs in the 2030s require monitoring. The stock offers dividend appeal with a $1.73 payout scheduled for August 2026.

D.R. Horton (DHI) trades at $151.08, up 3.47% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $153.00. The company reported Q3 2026 EPS of $3.20, beating estimates, but lowered full-year sales guidance amid persistent affordability pressures. Valuation metrics appear reasonable with a P/E of 14.4 and P/S of 1.32, while profitability remains solid with a net income margin of 9.15%.

The outlook is mixed: strong execution and cash returns provide support, but weaker demand and margin pressure pose headwinds. Investment opportunity lies in disciplined inventory management and shareholder returns, while risks include elevated mortgage rates and competitive threats from disruptors like Boxabl. Analyst sentiment is balanced with 45% buy ratings.